Phase II Study of Concurrent Chemoradiotherapy Using IMRT (With Single Photon Emission Computed Tomography/SPECT-CT to Define Functional Lung Volume and Positron Emission Tomography/PET to Define Gross Tumour Volume/GTV) and Docetaxel-cisplatin (or Carboplatin) Followed by Adjuvant Chemotherapy for Inoperable Stage III Non-small-cell Lung Cancer (NSCLC)
The duration of the study for each patient will include an up to 6-week screening phase, 12
weeks treatment phase (including a resting period of 2 weeks) followed by a long-term
follow-up.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Response rate (by contrast CT scan)
12 weeks after completion of adjuvant chemotherapy or within 4 weeks after premature study discontinuation
No
Clinical Sciences & Operations
Study Director
Sanofi
Hong Kong: Ethics Committee
DOCET_L_05158
NCT01266512
December 2010
December 2015
Name | Location |
---|